MARIA RODRIGUEZ-BARRADAS to Antiretroviral Therapy, Highly Active
This is a "connection" page, showing publications MARIA RODRIGUEZ-BARRADAS has written about Antiretroviral Therapy, Highly Active.
Connection Strength
1.658
-
Effect of combination antiretroviral treatment on total protein and calculated globulin levels among HIV-infected patients. Int J Infect Dis. 2010 Sep; 14 Suppl 3:e41-4.
Score: 0.304
-
Brief Report: Are Serious Falls Associated With Subsequent Fragility Fractures Among Veterans Living With HIV? J Acquir Immune Defic Syndr. 2021 10 01; 88(2):192-196.
Score: 0.170
-
Systemic Delays in the Initiation of Antiretroviral Therapy for Clinically Eligible HIV-Infected Patients in Houston, Texas: The Providers' Report Card. J Int Assoc Provid AIDS Care. 2018 Jan-Dec; 17:2325958218774042.
Score: 0.131
-
Adherence and HIV RNA Suppression in the Current Era of Highly Active Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2015 Aug 01; 69(4):493-8.
Score: 0.111
-
Antiretroviral therapy reduces the rate of hepatic decompensation among HIV- and hepatitis C virus-coinfected veterans. Clin Infect Dis. 2014 Mar; 58(5):719-27.
Score: 0.099
-
Intention to adhere to HIV treatment: a patient-centred predictor of antiretroviral adherence. HIV Med. 2013 Sep; 14(8):472-80.
Score: 0.094
-
Development and validation of a measure for intention to adhere to HIV treatment. AIDS Patient Care STDS. 2012 Jun; 26(6):329-34.
Score: 0.089
-
HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med. 2011 Feb 01; 183(3):388-95.
Score: 0.079
-
One year survival of HIV-infected veterans with CD4 < 100 cells/mm3: data from a veteran cohort. AIDS Care. 2010 Jul; 22(7):886-94.
Score: 0.078
-
Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression. J Acquir Immune Defic Syndr. 2009 Oct 01; 52(2):203-8.
Score: 0.074
-
Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine. Clin Infect Dis. 2003 Aug 01; 37(3):438-47.
Score: 0.048
-
Use of bDNA testing in the immunologically nonresponding patient who has a low or undetectable viral load by RT-PCR testing. HIV Clin Trials. 2003 Mar-Apr; 4(2):92-8.
Score: 0.047
-
Qualitative change in antibody responses of human immunodeficiency virus-infected individuals to pneumococcal capsular polysaccharide vaccination associated with highly active antiretroviral therapy. J Infect Dis. 2003 Mar 01; 187(5):758-68.
Score: 0.047
-
Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore). 2002 May; 81(3):213-27.
Score: 0.044
-
Patient- and provider-reported adherence: toward a clinically useful approach to measuring antiretroviral adherence. J Clin Epidemiol. 2001 Dec; 54 Suppl 1:S91-8.
Score: 0.043
-
Protease Inhibitors Do Not Affect Antibody Responses to Pneumococcal Vaccination. Clin Vaccine Immunol. 2016 06; 23(6):524-529.
Score: 0.029
-
Examining the link between patient satisfaction and adherence to HIV care: a structural equation model. PLoS One. 2013; 8(1):e54729.
Score: 0.023
-
Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT). HIV Med. 2011 Apr; 12(4):219-27.
Score: 0.020
-
Monocyte CD49e and 110-120 kDa fibronectin fragments: HIV prognostic indicators independent of viral load and CD4 T-cell counts. AIDS. 2009 Nov 13; 23(17):2247-53.
Score: 0.019
-
Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus. Pharmacotherapy. 2008 Mar; 28(3):323-30.
Score: 0.017
-
Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS. 2007 Jul 31; 21(12):1579-89.
Score: 0.016
-
Increased COPD among HIV-positive compared to HIV-negative veterans. Chest. 2006 Nov; 130(5):1326-33.
Score: 0.015
-
Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice. J Infect. 2004 Nov; 49(4):283-90.
Score: 0.013
-
Monocyte activation by circulating fibronectin fragments in HIV-1-infected patients. J Immunol. 2004 Aug 01; 173(3):2190-8.
Score: 0.013
-
Understanding racial disparities in HIV using data from the veterans aging cohort 3-site study and VA administrative data. Am J Public Health. 2003 Oct; 93(10):1728-33.
Score: 0.012
-
Clinical experience with human immunodeficiency virus-infected older patients in the era of effective antiretroviral therapy. Clin Infect Dis. 2002 Jun 01; 34(11):1530-3.
Score: 0.011
-
Transendothelial migration of leukocytes carrying infectious HIV-1: an indicator of adverse prognosis. AIDS. 2002 Jan 04; 16(1):5-12.
Score: 0.011